Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

Abstract

Although extensive data support a central pathogenic role for amyloid β protein (Aβ) in Alzheimer's disease1, the amyloid hypothesis remains controversial, in part because a specific neurotoxic species of Aβ and the nature of its effects on synaptic function have not been defined in vivo. Here we report that natural oligomers of human Aβ are formed soon after generation of the peptide within specific intracellular vesicles and are subsequently secreted from the cell. Cerebral microinjection of cell medium containing these oligomers and abundant Aβ monomers but no amyloid fibrils markedly inhibited hippocampal long-term potentiation (LTP) in rats in vivo. Immunodepletion from the medium of all Aβ species completely abrogated this effect. Pretreatment of the medium with insulin-degrading enzyme, which degrades Aβ monomers but not oligomers, did not prevent the inhibition of LTP. Therefore, Aβ oligomers, in the absence of monomers and amyloid fibrils, disrupted synaptic plasticity in vivo at concentrations found in human brain and cerebrospinal fluid. Finally, treatment of cells with γ-secretase inhibitors prevented oligomer formation at doses that allowed appreciable monomer production, and such medium no longer disrupted LTP, indicating that synaptotoxic Aβ oligomers can be targeted therapeutically.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: SDS-stable oligomers of Aβ are produced intracellularly and secreted.
Figure 2: SDS-stable oligomers are formed soon after generation of Aβ.
Figure 3: SDS-stable oligomers of human Aβ block hippocampal LTP in vivo.
Figure 4: γ-secretase inhibitors block Aβ oligomer formation at doses that allow substantial monomer production.

References

  1. 1

    Selkoe, D. J. Alzheimer's disease: genes, proteins and therapies. Physiol. Rev. 81, 742–761 (2001).

    Article  Google Scholar 

  2. 2

    Pike, C. J. Walencewicz, A. J., Glabe, C. G. & Cotman, C. W. In vitro aging of β-amyloid protein causes peptide aggregation and neurotoxicity. Brain Res. 563, 311–314 (1991).

    CAS  Article  Google Scholar 

  3. 3

    Lorenzo, A. & Yankner, B. A. β-amyloid neurotoxicity requires fibril formation and is inhibited by congo red. Proc. Natl Acad. Sci. USA 91, 12243–12247 (1994).

    ADS  CAS  Article  Google Scholar 

  4. 4

    Terry, R. D. et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol. 30, 572–580 (1991).

    CAS  Article  Google Scholar 

  5. 5

    Dickson, D. W. et al. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol. Aging 16, 285–298 (1995).

    CAS  Article  Google Scholar 

  6. 6

    Lue, L. F. et al. Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155, 853–862 (1999).

    ADS  CAS  Article  Google Scholar 

  7. 7

    McLean, C. A. et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. 46, 860–866 (1999).

    CAS  Article  Google Scholar 

  8. 8

    Podlisny, M. B. et al. Aggregation of secreted amyloid β-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J. Biol. Chem. 270, 9564–9570 (1995).

    CAS  Article  Google Scholar 

  9. 9

    Morishima-Kawashima, M. & Ihara, Y. The presence of amyloid β-protein in the detergent-insoluble membrane compartment of human neuroblastoma cells. Biochemistry 37, 15247–15253 (1998).

    CAS  Article  Google Scholar 

  10. 10

    Walsh, D. M., Tseng, B. P., Rydel, R. E., Podlisny, M. B. & Selkoe, D. J. Detection of intracellular oligomers of amyloid β-protein in cells derived from human brain. Biochemistry 39, 10831–10839 (2000).

    CAS  Article  Google Scholar 

  11. 11

    Xia, W. M. et al. Enhanced production and oligomerization of the 42-residue amyloid β-protein by Chinese hamster ovary cells stably expressing mutant presenilins. J. Biol. Chem. 272, 7977–7982 (1997).

    CAS  Article  Google Scholar 

  12. 12

    Hsia, A. Y. et al. Plaque-independent disruption of neural circuits in Alzheimer's disease mouse model. Proc. Natl Acad. Sci. USA 96, 3228–3233 (1999).

    ADS  CAS  Article  Google Scholar 

  13. 13

    Mucke, L. et al. High-level neuronal expression of Aβ1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J. Neurosci. 20, 4050–4058 (2000).

    CAS  Article  Google Scholar 

  14. 14

    Hartley, D. M. et al. Protofibrillar intermediates of amyloid β-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J. Neurosci. 19, 8876–8884 (1999).

    CAS  Article  Google Scholar 

  15. 15

    Xia, W. et al. Presenilin complexes with the C-terminal fragments of amyloid precursor protein at the sites of amyloid β-protein generation. Proc. Natl Acad. Sci. USA 97, 9299–9304 (2000).

    ADS  CAS  Article  Google Scholar 

  16. 16

    Kim, J. H., Anwyl, R., Suh, Y. H., Djamgoz, M. B. & Rowan, M. J. Use-dependent effects of amyloidogenic fragments of β-amyloid precursor protein on synaptic plasticity in rat hippocampus in vivo. J. Neurosci. 21, 1327–1333 (2001).

    CAS  Article  Google Scholar 

  17. 17

    Qiu, W. Q. et al. Insulin-degrading enzyme regulates extracellular levels of amyloid β-protein by degradation. J. Biol. Chem. 273, 32730–32738 (1998).

    CAS  Article  Google Scholar 

  18. 18

    Lambert, M. P. et al. Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc. Natl Acad. Sci. USA 95, 6448–6453 (1998).

    ADS  CAS  Article  Google Scholar 

  19. 19

    Walsh, D. M. et al. Amyloid β-protein fibrillogenesis: structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274, 25945–25952 (1999).

    CAS  Article  Google Scholar 

  20. 20

    Chui, D.-H. et al. Transgenic mice with Alzheimer presenilin 1 mutations show accelerated neurodegeneration without amyloid plaque formation. Nature Med. 5, 560–564 (1999).

    CAS  Article  Google Scholar 

  21. 21

    Chen, G. et al. A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease. Nature 408, 975–979 (2000).

    ADS  CAS  Article  Google Scholar 

  22. 22

    Lewis, J. et al. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293, 1487–1491 (2001).

    ADS  CAS  Article  Google Scholar 

  23. 23

    Larson, J., Lynch, G., Games, D. & Seubert, P. Alterations in synaptic transmission and long-term potentiation in hippocampal slices for young and aged PDAPP mice. Brain Res. 840, 23–35 (1999).

    CAS  Article  Google Scholar 

  24. 24

    Moechars, D. et al. Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483–6492 (1999).

    CAS  Article  Google Scholar 

  25. 25

    Chapman, P. F. et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nature Neurosci. 2, 271–276 (1999).

    CAS  Article  Google Scholar 

  26. 26

    Fitzhohn, S. M. et al. Age-related impairment of synaptic transmission but normal long-term potentiation in transgenic mice that overexpress the human APP695SWE mutant form of amyloid precursor protein. J. Neurosci. 21, 4691–4698 (2001).

    Article  Google Scholar 

  27. 27

    Rochet, J. C. & Lansbury, P. T. Jr Amyloid fibrillogenesis: themes and variations. Curr. Opin. Struct. Biol. 10, 60–68 (2000).

    CAS  Article  Google Scholar 

  28. 28

    Chiti, F. et al. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl Acad. Sci. USA 96, 3590–3590 (1999).

    ADS  CAS  Article  Google Scholar 

  29. 29

    Chesneau, V. & Rosner, M. R. Functional human insulin-degrading enzyme can be expressed in bacteria. Protein Expr. Purif. 19, 91–98 (2000).

    CAS  Article  Google Scholar 

  30. 30

    Getman, D. P. et al. Discovery of a novel class of potent HIV-1 protease inhibitors containing the (R)-(hydroxyethyl)urea isostere. J. Med. Chem. 36, 288–291 (1993).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We thank M. Rosner and V. Chesneau for the gift of the pProExH6HA IDE expression vector, B. Zheng for ELISA analysis, S. Mansourian for assistance in the preparation of illustrations and W. T. Kimberly, W. P. Esler and D. M. Hartley for discussions. Supported by NIH grants (to D.J.S. and M.S.W.) and by Enterprise Ireland and the Health Research Board Ireland (M.R. and R.A.).

Author information

Affiliations

Authors

Corresponding author

Correspondence to Dennis J. Selkoe.

Ethics declarations

Competing interests

The authors declare that they have no competing financial interests

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Walsh, D., Klyubin, I., Fadeeva, J. et al. Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416, 535–539 (2002). https://doi.org/10.1038/416535a

Download citation

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing